|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
CAS 905854-02-6 Tivantinib Chemical Report & Database ... listed. The substance covered (Tivantinib) are classified by the ... & Database definitions: Name: Tivantinib: Tivantinib; ARQ 197; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij] ... Chemical or Reaction Intermediate The Tivantinib Report & Database gives Market ... Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insight Change is coming to the NSCLC treatment algorithm—and it’s coming soon. Revolutionary new immunotherapies, more personalised treatment choices and further drug developments are all set to roll out in the near future. What are the potential blockbusters, ... ASCO 2014 -- Delegate Physicians Rate Influence and Impact ... ), Xalkori (Pfizer), Iressa (AstraZeneca) and tivantinib (ArQule) Which presentation topics were ... ARQULE - Positive Data in HCC is an Add-On! Positive PhII data of Tivantinib (formerly ARQ-197, c-MET ... drugs available for this indication. Tivantinib showed statistically significant improvement of 56% in ... efficacy bar for Tivantinib. We remain positive on an approval of Tivantinib in its lead ... ARQULE - Read-Out Only in 2013 We remain positive on potential of Tivantinib (formerly ARQ-197, PhIII, c-MET ... Rising Stars (Small-Mid Cap) Biotech/Biopharma: Investment Opportunities ... Star companies: ARQL: Key Driver is Tivantinib (c-MET inhibitor) in PhIII for 2nd ... |